News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones.
Read
Week In Review: InvoX, A Sino Biopharma Company, To Pay $161 Million To Acquire F-Star
InvoX Pharma, a Sino Biopharma subsidiary, will pay $161 million to acquire F-Star, a clinical stage company developing bispecific drugs for immunotherapies. Meanwhile, Reistone Biopharma completed a Series A financing of nearly $100 million.
Read
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global expansion.
Read
Week In Review: Fosun Pays $158 Million For Controlling Stake In Singapore Medical Centers
Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. Oncocare is one of Singapore’s largest private medical oncology specialist centers.
Read
Week In Review: Vivo Raises $600 Million In First Tranche Of China PE Fund
Vivo Capital held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. Meanwhile, ProfoundBio closed a $70 million Series A+ financing round led by Sequoia China.
Read
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and milestone payments, plus tiered royalties.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications